Previously published reports provided clinicians with guidelines for managing pharmacologic interactions that can result from concomitant protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) and rifamycin therapy. A group of CDC scientists and outside expert consultants recently updated the guidelines. The revised guidelines are available at http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/toc.htm.
